Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole by Bell, Lauren Nicole et al.
1852  •  J Clin Pharmacol 2012;52:1852-1860
Third-generation aromatase inhibitors (AIs) are increasingly being used as endocrine therapy for 
postmenopausal women diagnosed with hormone 
receptor–positive breast cancer. Although the 2 non-
steroidal AIs (anastrozole and letrozole) and the 
steroidal inactivator (exemestane) all substantially 
decrease whole-body aromatization in postmeno-
pausal women,1-4 the chemical structures and mech-
anisms of action of these compounds vary.
Patients treated with AIs experience approxi-
mately 98% inhibition of aromatase enzyme 
action,1,2,5 leading to a high level of estrogen depriva-
tion. Although estrogen reduction is central to the 
treatment of hormone receptor–positive breast can-
cer, estrogens have other physiological effects. 
Importantly, estrogen deprivation in postmenopau-
sal women has been shown to affect lipid concentra-
tions, bone metabolism, and the incidence of 
cardiovascular disease.6 As postmenopausal women 
are already at increased risk for altered lipid profiles 
Effects of aromatase inhibitor (AI) therapy on the plasma 
lipid profile are not clear. Here the authors describe 
changes in fasting lipids (total cholesterol, high-density 
lipoprotein [HDL], low-density lipoprotein [LDL], and tri-
glycerides) before and after 3 months of exemestane or 
letrozole treatment. HDL was reduced in the entire cohort 
(P < .001) and in the exemestane group (P < .001) but 
unchanged in the letrozole group (P = .169). LDL was 
increased in the entire cohort (P = .005) and in the letro-
zole group (P = .002) but unchanged in the exemestane 
group (P = .361). This effect was at least partially attribut-
able to washout of tamoxifen as only patients with prior 
use of tamoxifen experienced a significant increase in 
LDL. Baseline HDL was an independent predictor of the 
change in HDL (r2 = –0.128, P < .001), and prior tamoxifen 
use was associated with greater increases in LDL (r2 = 0.057, 
P < .001). Use of lipid-altering medications did not pro-
tect against the exemestane-induced drop in HDL or the 
increase in LDL observed in women with prior use of 
tamoxifen taking letrozole. In conclusion, AI treatment 
and/or washout of tamoxifen induced detrimental changes 
in the lipid profile of postmenopausal women with breast 
cancer.
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and cardiovascular disease, it is necessary to pro-
spectively examine the effects of using steroidal and 
nonsteroidal AIs on lipid parameters in this popula-
tion.
Overall, indirect comparisons of the efficacy and 
safety profiles of the steroidal and nonsteroidal AIs, 
when used in the adjuvant setting, suggest they are 
similar.4,7-9 Previous studies investigating the effects 
of exemestane and letrozole on several lipid param-
eters have produced mixed results.10-17 The causes of 
this variability in response are unknown but may be 
due to differences in study design and genetic and/or 
population differences among the patient cohorts. 
The COnsortium on BReast cancer phArmacogenom-
ics (COBRA) is conducting a multicenter, prospective 
randomized clinical trial with a primary goal of 
investigating the pharmacogenomics of 2 AIs, ex-
emestane and letrozole (ELPh trial; Exemestane and 
Letrozole Pharmacogenomics). A key objective of 
this trial is to evaluate, prospectively, the effects of 3 
months of AI treatment on the fasting lipid panel.
METhodS
Participants. This prospective lipid panel analysis 
was conducted as one component of a prospective, 
multi-institutional, randomized observational open-
label clinical trial of postmenopausal women for 
whom treatment with an AI was appropriate. The 
study design is listed on http://www.clinicaltrials.
gov (NCT00228956) and was previously described 
in detail.18 Overall, 503 women enrolled in the study 
from August 2005 to July 2009. Participants were 
eligible if they were postmenopausal, diagnosed 
with hormone receptor–positive ductal carcinoma 
in situ (DCIS/stage 0) or stage I to III invasive breast 
cancer, and considering AI therapy either as initial 
adjuvant endocrine therapy or after 1 to 5 years of 
tamoxifen treatment. Patients were excluded from 
the study if they had a history of bilateral mastectomy 
or radiation to the contralateral breast, prior use of 
an aromatase inhibitor, or a history of ovarian can-
cer, endometrial cancer, cancer of the fallopian tube, 
or primary peritoneal carcinomatosis. Patients were 
recruited to the cohort from the breast cancer clinics 
at the University of Michigan Comprehensive Cancer 
Center, the Sidney Kimmel Comprehensive Cancer 
Center at Johns Hopkins, and the Melvin and Bren 
Simon Cancer Center at the Indiana University School 
of Medicine. The institutional review board at each 
study site approved the study, and all participants 
gave written informed consent.
Patients were stratified based on prior chemo-
therapy, prior tamoxifen, and prior bisphosphonate 
use and must have completed recommended local 
therapy as well as any adjuvant chemotherapy, 
including tamoxifen, prior to initiation of aromatase 
inhibitor treatment. Patients were randomly assigned 
to receive either exemestane (Aromasin; Pfizer, Inc, 
New York, New York; 25 mg orally per day) or letro-
zole (Femara; Novartis Pharmaceuticals Corporation, 
East Hanover, New Jersey; 2.5 mg orally per day) for 
2 years. Pretreatment medical histories, medication 
lists, physical examinations, and laboratory samples 
were obtained for each patient at baseline and after 
3 months of AI treatment.
Patients were excluded from this lipid analysis if 
samples were not available at both the baseline and 
3-month time points, if they were not fasting at 
the time of blood draw, or if they discontinued the 
assigned AI medication before the 3-month time 
point. Women with an established lipid-altering 
treatment regimen (including a statin, fibrate, and/or 
ezetimibe) prior to enrollment in the ELPh trial who 
continued on this therapy throughout the 3-month 
study period without any changes in type or dose of 
drug were included in a separate substudy. Women 
who started or stopped taking a lipid-altering medi-
cation or changed drug or dose during the 3-month 
study period were excluded from both analyses.
Sample collection and measurement of lipid pro-
files. Venous blood samples for lipid panel analyses 
were collected at the baseline and 3-month follow-up 
visit after an overnight (at least 12-hour) fast. Total 
cholesterol, high-density lipoprotein (HDL) choles-
terol, low-density lipoprotein (LDL) cholesterol, and 
triglycerides (TG) were analyzed at the clinical labo-
ratories at the University of Michigan Health System, 
the Johns Hopkins Medical Laboratories, and the 
Indiana University Clarian Pathology Laboratory. All 
test centers met Clinical Laboratory Improvement 
Amendments (CLIA) standards.
Statistical analysis. Basic descriptive statistics, 
including means, standard deviations (SD), ranges, 
and percentages, were used to characterize the study 
participants. Paired and unpaired Student t tests 
were used to compare differences in lipid panel vari-
ables at baseline and after 3 months of AI treatment. 
Pearson’s correlation coefficients were used to test for 
associations between lipid profile parameters and 
descriptive variables. When appropriate, stepwise reg-
ression analysis was used to take into account the linear 
effect of several independent variables predicting the 
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dependent variable. Statistical analyses were per-
formed using SPSS 16.0 for Windows (SPSS, Inc, an 
IBM Company, Chicago, Illinois). A P < .05 was con-
sidered statistically significant.
RESuLTS
Study population. Of the 503 women enrolled in the 
ELPh clinical trial, 246 were eligible for inclusion in 
the overall lipid analysis (CONSORT diagram shown 
in Figure 1 and baseline patient characteristics 
shown in Table I). Women were excluded due to 
incomplete sampling (n = 21), sampling under non-
fasting conditions (n = 49), use of lipid-altering 
medications (n = 123), or early discontinuation of AI 
treatment or crossover of AI assignment due to intol-
erability (n = 61). Patient characteristics for the indi-
vidual exemestane (n = 117) and letrozole (n = 129) 
groups are also included in Table I.
Lipid profiles. Fasting lipid concentrations before 
and after AI treatment are shown in Table II. In the 
overall lipid analysis cohort, there was no significant 
change in total cholesterol (0.3 ± 27 mg/dL; P = .847), 
but AI therapy induced a 4 ± 9-mg/dL reduction in 
HDL cholesterol (P < .001) and a 5 ± 26-mg/dL 
increase in LDL concentration (P = .005). These 
changes resulted in a significant increase in the 
LDL/HDL ratio in the entire patient cohort (P < .001).
Lipid changes were also analyzed by specific 
agent subgroup. In the exemestane group, total cho-
lesterol was reduced by 8 ± 28 mg/dL (P = .003), HDL 
concentrations fell (–8 ± 9 mg/dL; P < .001), LDL did 
not change significantly (2 ± 27 mg/dL; P = .361), 
but the LDL/HDL ratio was significantly increased 
(P < .001). In addition, triglycerides were signifi-
cantly decreased by 12 ± 42 mg/dL (P = .003). In the 
letrozole group, total cholesterol was increased by 
8 ± 24 mg/dL (P < .001), HDL concentrations did not 
change significantly (–1 ± 9 mg/dL; P = .169), LDL 
concentrations increased 7 ± 25 mg/dL (P = .002), 
and the LDL/HDL ratio was significantly increased 
(P < .001). Overall, our data revealed a shift in HDL 
cholesterol distribution toward lower concentra-
tions in the exemestane group (Figure 2, top panel) 
but no change in HDL in the letrozole group (Figure 2, 
bottom panel) after 3 months of AI therapy. This 
frequency distribution analysis revealed significant 
interindividual variation among patients.
Relationship between AI-induced changes in lipid 
parameters and patient characteristics. Correlates of 
Figure 1. CONSORT diagram of included and excluded participants in this lipid analysis. AI, aromatase inhibitor.
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the changes in HDL and LDL cholesterol induced by 
AI therapy in the entire lipid analysis cohort (n = 246) 
summarized in Table III. Univariate analysis 
revealed a significant association between the 
AI-induced change in HDL cholesterol and baseline 
lipid profiles. HDL was more likely to decline after 
Table II Change in Lipid Parameters After 3 Months of Aromatase Inhibitor  
Therapy in the Overall Lipid Analysis Cohort (n = 246)





Value Baseline 3 Months
Change, Mean ± 
Sd (%)
P 








208 ± 35 208 ± 33 0.3 ± 27 (<1) .847 212 ± 36 205 ± 34 −8 ± 28 (4) .003 203 ± 35 211 ± 33 8 ± 24 (4) <.001
HDL, mg/dL 62 ± 17 57 ± 17 −4 ± 9 (7) <.001 63 ± 18 55 ±16 −8 ± 9 (12) <.001 60 ± 17 59 ± 17 −1 ± 9 (2) .169
LDL, mg/dL 124 ± 32 129 ± 29 5 ± 26 (4) .005 127 ± 32 129 ± 28 2 ± 27 (2) .361 121 ± 31 128 ± 30 7 ± 25 (5) .002
LDL/HDL 
Ratio
2.2 ± 0.9 2.4 ± 0.9 0.2 ± 0.6 (8) <.001 2.2 ± 0.9 2.5 ± 0.9 0.3 ± 0.6 (12) <.001 2.2 ± 0.9 2.4 ± 0.9 0.2 ± 0.5 (8) <.001
TG, mg/dL 111 ± 53 106 ± 48 −5 ± 43 (5) .053 112 ± 53 101 ± 45 −12 ± 42 (10) .003 110 ± 54 110 ± 50 0.4 ± 43 (<1) .922
Values are shown as mean ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.
Table I Baseline Characteristics of Patients Included in Lipid Panel Study



















Group (n = 54)
Age, y, mean (range) 58 (38-85) 59 (44-85) 57 (38-80) 62 (44-84) 61 (44-83) 63 (49-84)
Body mass index, kg/m2, 
mean (SD)
29.3 (6.1) 29.6 (6.3) 29.0 (5.9) 31.5 (6.9) 30.7 (5.7) 32.2 (7.6)
Race/ethnicity, No. (%)
 African American 25 (10) 9 (8) 16 (12) 9 (9) 3 (7) 6 (11)
 White 214 (87) 104 (89) 110 (85) 84 (88) 38 (93) 46 (85)
 Asian  6 (2) 3 (3) 3 (2) 2 (2) 0 2 (4)
 Other    1 (<1) 1 (<1)  0 0 0 0
Prior chemotherapy,  
No. (%)
120 (49) 51 (44) 69 (53) 31 (33) 13 (32) 18 (33)
Prior tamoxifen use,  
No. (%)
93 (38) 38 (32) 55 (43) 30 (32) 13 (32) 17 (31)
  Duration of tamoxifen  
  therapy, y, mean (SD)




38 (15) 19 (16) 19 (15) 16 (17) 9 (22) 7 (13)
Lipid-Altering Medications, 
No. (%)a
Statins 86 (91) 37 (90) 49 (91)
Fibrates 6 (6) 1 (2) 5 (9)
Ezetimibe 10 (11) 5 (12) 5 (9)
a. Please note that 7 women were taking 2 lipid-altering medications: statin + ezetimibe (n = 5) and statin + fibrate (n = 2).
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3 months of therapy with either AI in women whose 
baseline total cholesterol or HDL cholesterol was 
high (correlation between change in HDL cholesterol 
with baseline total cholesterol: r2 = –0.023, P = .017 
and baseline HDL cholesterol: r2 = –0.125, P < .001). 
Therefore, there was a statistically significant posi-
tive association between the AI-induced reduction 
in HDL cholesterol and the baseline LDL/HDL ratio 
(r2 = 0.054, P < .001). Upon multivariate regression 
analysis in which baseline total cholesterol, baseline 
HDL cholesterol, and the baseline LDL/HDL ratio 
were considered, only baseline HDL cholesterol 
(r2 = –0.125, P < .001) remained a significant predic-
tor of the reduction in HDL following AI treatment 
(Figure 3, top panel). Baseline HDL cholesterol was 
also identified as an independent predictor of the 
change in HDL when the exemestane group was 
examined separately (r2 = –0.253, P < .001).
The change in LDL cholesterol in the entire lipid 
analysis cohort was significantly correlated with 
baseline total cholesterol (r2 = –0.178, P < .001), base-
line LDL cholesterol (r2 = –0.252, P < .001), and base-
line LDL/HDL ratio (r2 = –0.088, P < .001), as well 
as positively associated with prior tamoxifen use 
(r2 = 0.123, P < .001). Upon multivariate regression 
analysis in which baseline total cholesterol, base-
line LDL cholesterol, baseline LDL/HDL ratio, and 
prior tamoxifen use were considered, both baseline 
LDL cholesterol (r2 = –0.192, P < .001) and prior 
tamoxifen use (r2 = 0.051, P < .001) remained statisti-
cally significant predictors of the change in LDL 
cholesterol (Figure 3, bottom panel). Baseline LDL 
cholesterol (r2 = 0.153, P < .001) and prior use of 
tamoxifen (r2 = 0.098, P < .001) were also identified 
as independent predictors of the change in LDL cho-
lesterol when the letrozole group was examined 
separately.
Prior use of tamoxifen was identified as an inde-
pendent predictor of the change in LDL cholesterol; 
therefore, patients were stratified by this variable, 
and changes in lipid parameters were analyzed as 
shown in Supplementary Table SI. Briefly, prior use 
Figure 2. Distributions of the change in high-density lipoprotein 
(HDL) cholesterol in the exemestane group (n = 117; top panel) 
and letrozole group (n = 129; bottom panel) after 3 months of 
aromatase inhibitor (AI) therapy. The frequency (% of patients) 
is shown on the y-axis, and the change in HDL cholesterol 
concentration (mg/dL) is shown on the x-axis. The HDL 
categories were selected arbitrarily, and no test statistics were 
conducted.
Table III Univariate and Multivariate Analysis  
of Predictors of the Change in HDL and LDL 
Cholesterol After 3 Months of Aromatase  
Inhibitor Therapy in the Overall Lipid  
Analysis Cohort (n = 246)
Change Correlates
hdL Cholesterol LdL Cholesterol
Baseline total cholesterol  
(r2 = –0.023, P = .017)
Baseline HDL cholesterola  
(r2 = –0.125, P < .001) 
Baseline LDL/HDL ratio  
(r2 = 0.054, P < .001)
Baseline total cholesterol 
(r2 = –0.178, P <.001) 
Baseline LDL cholesterola 
(r2 = –0.252, P < .001) 
Baseline LDL/HDL ratio 
(r2 = –0.088, P < .001) 
Prior tamoxifen usea  
(r2 = 0.123, P < .001)
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a. Independent predictors upon stepwise regression analysis.
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of tamoxifen did not affect the exemestane-induced 
reduction in HDL cholesterol (P < .001) but was at 
least partially responsible for observed elevations in 
LDL cholesterol in the letrozole group, as only 
women who stopped tamoxifen treatment experi-
enced a significant increase in LDL (P < .001).
Lipid-altering medication cohort substudy. Of the 
123 women taking a lipid-altering medication prior 
to initiating AI therapy, 95 were eligible for inclusion 
in the lipid analysis (Figure 1). In addition to the 
exclusion criteria described above for the overall 
lipid analysis, women were specifically excluded 
from this cohort if they did not have an established 
lipid-lowering treatment regimen prior to enroll-
ment or if they changed lipid-altering drugs or doses 
during the 3-month study period (n = 28). Baseline 
characteristics of patients included in the lipid-
altering medication substudy are shown in Table I. 
Women included in this cohort were significantly 
older (mean ± SD age 62.4 ± 8.9 years vs 58.2 ± 7.9 
years; P < .001) and heavier (body mass index [BMI] 
31.5 ± 6.9 kg/m2 vs 29.3 ± 6.1 kg/m2; P = .003), but 
all other patient demographics and treatment histo-
ries were similar to those in the overall lipid analy-
sis cohort (Table I).
Lipid panel measures for women included in the 
lipid-altering medication cohort, before and after 3 
months of AI treatment, are shown in Table IV. 
Baseline total cholesterol, HDL, and LDL concentra-
tions (all P < .001) and LDL/HDL ratio (P = .005) 
were significantly lower in women taking lipid-
altering medications compared to those in the over-
all lipid analysis cohort, but triglycerides did not 
differ substantially between the 2 patient groups 
(P = .067). Similar to the observation in the overall 
lipid analysis, 3 months of AI therapy induced a 
significant decrease in total cholesterol (–7 ± 20 mg/
dL; P = .001) and a reduction in HDL cholesterol 
(–4 ± 7 mg/dL; P < .001). As was seen in the exemestane-
treated cohort in the overall lipid analysis, women 
taking exemestane in the lipid-altering medication 
cohort also had significantly reduced total choles-
terol (–12 ± 22 mg/dL; P = .001), HDL cholesterol 
(–5 ± 8 mg/dL; P < .001), and triglycerides (–20 ± 54 
mg/dL; P = .024). The only AI-induced change 
observed in the letrozole-treated lipid-altering medi-
cation group was a reduction in HDL cholesterol of 
4 ± 7 mg/dL (P = .001). Due to the effects of tamox-
ifen washout, women included in the lipid-altering 
medication cohort were also stratified by prior use of 
tamoxifen, and changes in lipid panel parameters 
were analyzed (Supplementary Table SII).
dISCuSSIoN
Results from the lipid panel study within the pro-
spective clinical trial described here demonstrate 
important negative effects of 3 months of AI treat-
ment and/or washout of tamoxifen on the fasting 
lipid profile of postmenopausal women with breast 
cancer. Adverse effects on the lipid panel are not 
desirable as cholesterol and triglyceride concentrations 
are often used as a surrogate indicator for long-term 
cardiovascular risk. Overall, women on exemestane 
Figure 3. Significant predictors of the change in high-density 
lipoprotein (HDL) cholesterol (top panel) and low-density 
lipoprotein (LDL) cholesterol (bottom panel) induced by 
aromatase inhibitor (AI) therapy in the overall lipid analysis 
cohort (n = 246). Baseline HDL cholesterol was also identified 
as an independent predictor of the change in HDL when the 
exemestane group was examined separately (r2 = –0.253,  
P < .001). Prior use of tamoxifen was an independent predictor 
of the change in LDL cholesterol in both the overall lipid analysis 
cohort (bottom panel) and the letrozole group alone (P < .001).
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therapy exhibited reduced total and HDL choles-
terol and triglycerides, whereas treatment with 
letrozole increased total and LDL cholesterol in 
women with prior use of tamoxifen. This resulted in 
a significant 12% and 8% elevation in the LDL/HDL 
ratio in the exemestane group (P < .001) and the 
letrozole group (P < .001), respectively. Women tak-
ing lipid-altering medications were not protected 
from changes in their lipid profile, as both the drop 
in HDL cholesterol induced by exemestane treat-
ment and the elevation in LDL cholesterol in women 
with prior use of tamoxifen taking letrozole were 
observed in this cohort. Furthermore, letrozole treat-
ment did not substantially affect HDL cholesterol in 
the overall analysis, but women taking both letro-
zole and lipid-altering medications experienced a 
significant reduction in HDL cholesterol.
To date, several clinical trials have proven the 
efficacy of the third-generation AIs such as exemes-
tane and letrozole in the treatment of breast cancer 
and shown that AI treatment, in some settings, may 
be superior to the previously established tamoxifen 
treatment regimen.3,7-9,19 The clinical trial described 
herein is the first designed as a direct, head-to-head 
comparison of a steroidal AI (exemestane) with a 
nonsteroidal AI (letrozole) in postmenopausal 
women with breast cancer. To the best of our knowl-
edge, this study is also the first to independently 
analyze a group of women taking an AI plus lipid-
altering medications, as previous reports either do 
not address this point or list use of medications 
known to affect lipids as exclusion criteria. Therefore, 
the unfavorable lipid profile changes after just 
3 months of AI therapy/tamoxifen washout observed 
in our large patient cohort are an important addi-
tion to data previously reported regarding the effects 
of exemestane and letrozole on lipid concentrations 
and provide important information for prescribers to 
be aware of. Three recent studies have demon-
strated a reduction in HDL cholesterol induced by 
exemestane treatment, as was observed in the pre-
sent study.10-12 In 2 conflicting reports, a largely 
neutral effect of exemestane on the lipidemic pro-
file was demonstrated.13-15 As is the case for exemes-
tane, clinical trials investigating lipid effects of the 
nonsteroidal AI letrozole also have divergent find-
ings. In an early study, letrozole treatment was 
shown to significantly increase total and LDL cho-
lesterol.16 Subsequently, Wasan et al17 demonstrated 
that letrozole therapy did not significantly alter 
lipid parameters.
Differences in study design, prior tamoxifen use, 
and inclusion/exclusion of patients on lipid-altering 
medications likely contribute to the variability seen 
in AI-induced changes, or lack thereof, in lipid pro-
files. For example, we observed that prior use of 
tamoxifen is a significant independent predictor of 
increased LDL cholesterol in both the entire patient 
cohort and in the letrozole cohort. There is defini-
tive evidence that tamoxifen reduces LDL choles-
terol20-26; therefore, our observation is consistent 
with previous tamoxifen studies. Although women 
in our study had differing durations of tamoxifen 
therapy, a plausible explanation is that this treatment 
reduced their LDL cholesterol and, upon cessation 
of tamoxifen therapy, they experienced loss of this 
positive effect on LDL from tamoxifen. It is impor-
tant to note that in women with prior use of tamoxifen, 
elevations in LDL cholesterol were not as pronounced 
in the exemestane group as in the letrozole group, 
especially in the lipid-altering medication cohort. 
This raises the possibility that letrozole treatment 
Table IV Change in Lipid Parameters After 3 Months of Aromatase Inhibitor Therapy  
in the Lipid-Altering Medication Analysis (n = 95)
Lipid-Altering Medication Cohort (n = 95) Exemestane + Lipid-Altering Medication 
Group (n = 41)
Letrozole + Lipid-Altering Medication 









Value Baseline 3 Months
Change, 







176 ± 32 168 ± 30 −7 ± 20 (4) .001 180 ± 31 167 ± 30 −12 ± 22 (7) .001 173 ± 32 169 ± 29 −3 ± 18 (2) .172
HDL, mg/dL 54 ± 15 50 ± 13 −4 ± 7 (8) <.001 54 ± 12 49 ± 12 −5 ± 8 (10) <.001 54 ± 17 50 ± 15 −4 ± 7 (7) .001
LDL, mg/dL 97 ± 26 95 ± 23 −3 ± 19 (3) .186 100 ± 26 96 ± 24 −4 ± 21 (4) .239 95 ± 27 93 ± 22 −2 ± 18 (2) .502
LDL/HDL 
Ratio
1.9 ± 0.7 2.0 ± 0.7 0.1 ± 0.5 (5) .071 1.9 ± 0.7 2.1 ± 0.6 0.2 ± 0.5 (10) .123 1.9 ± 0.8 2.0 ± 0.7 0.1 ± 0.5 (5) .310
TG, mg/dL 124 ± 59 120 ± 53 −4 ± 48 (3) .463 129 ± 64 109 ± 43 −20 ± 54 (15) .024 120 ± 55 128 ± 59 9 ± 40 (7) .112
Values are shown as mean ± SD. HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.
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itself may, in fact, increase LDL cholesterol in some 
women.
Although exemestane and letrozole are both clas-
sified as AIs, there are substantial differences in 
their chemical structures and mechanisms of action. 
Exemestane is a steroid-based inactivator that func-
tions as a suicidal inhibitor of aromatase enzyme. 
Importantly, an early in vitro study showed that a 
metabolite of exemestane, 17-hydroxy exemestane, 
may elicit androgenic effects through binding to the 
androgen receptor.27 Because previous work has 
shown that exogenous androgens have a significant 
detrimental effect on HDL cholesterol in postmeno-
pausal women,28 we hypothesize that this may be a 
potential mechanism by which exemestane and/or 
17-hydroxy exemestane could reduce HDL choles-
terol. In addition, baseline total and HDL cholesterol 
were slightly higher in the exemestane group, and 
because both were identified as predictors of the 
change in HDL cholesterol, this cannot be excluded 
as a contributing factor to the reduction in HDL cho-
lesterol observed in patients treated with exemes-
tane. Metabolism of letrozole does not lead to 
production of an androgenic metabolite; therefore, 
less is currently known about mechanisms by which 
letrozole may potentially induce changes in lipids.
Regardless of how and to what extent exemestane 
or letrozole treatment and/or tamoxifen washout 
reduce HDL and increase LDL cholesterol, respec-
tively, a detrimental effect on the lipid profile is 
not ideal as postmenopausal women are already at 
increased risk for cardiovascular disease. As the 
potential use of AIs expands beyond the context of 
adjuvant therapy for postmenopausal women diag-
nosed with breast cancer to chemoprevention for 
high-risk women,29 consideration of the risk-benefit 
ratio is increasingly important. The large interindi-
vidual variability of AI-induced changes in HDL 
cholesterol is shown in Figure 2. Future study will 
be directed at identifying women who may benefit 
most from treatment with an AI and/or tamoxifen 
while also avoiding unfavorable adverse effects.
The effects of AI-induced changes in cholesterol on 
the risk of cardiovascular events have not been estab-
lished, although a recent review of the AI clinical trials 
showed no significant increases in cardiovascular-
related adverse events compared to tamoxifen or pla-
cebo.30 In addition, a meta-analysis of randomized 
clinical trials with AIs showed no increase in non-
breast deaths with AI treatment.3 However, it would 
likely take many additional years of study to clearly 
define the cardiovascular effects of AI therapy. A para-
dox exists with tamoxifen, which has a positive effect 
on the lipid profile20-26 and may reduce the risk of 
cardiovascular disease31 but increases the incidence of 
thromboembolic events and ischemic stroke.6 Because 
AIs do not have estrogenic agonist effects, it is unlikely 
that a similar contradiction exists with AIs. Nonetheless, 
results from this lipid analysis support the notion that 
monitoring of cardiovascular morbidity and mortality 
in all long-term AI trials will be necessary. In addition, 
use of lipid-altering drugs did not convey protection 
from the AI-induced adverse effects on HDL choles-
terol, which could potentially increase cardiovascular 
risk over time. Furthermore, women who experienced 
the greatest changes in lipids (that resulted in starting/
stopping or dose adjustment of lipid-altering medica-
tions) were not included in these analyses, and this 
important point should be taken into consideration 
when interpreting study results.
In conclusion, we observed an unfavorable effect 
of AI treatment alone or in combination with tamox-
ifen washout on the lipid panel of postmenopausal 
women with breast cancer and found that use of 
lipid-altering medications did not protect against 
the HDL-lowering effects of exemestane therapy. A 
better understanding of the side effect profile, along 
with identification of the genetic factors that can 
predict adverse events, may eventually provide the 
framework for making optimal AI therapy decisions 
for women with breast cancer.
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